Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations (SURF-201)

NCT06160752 is registered in ClinicalTrials.gov with Tyra Biosciences, Inc as lead sponsor.

NCT NCT06160752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06160752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations (SURF-201)
Lead sponsor
Tyra Biosciences, Inc
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 22, 2023
Completion date
September 30, 2027
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma, locally advanced cholangiocarcinoma, metastatic cholangiocarcinoma, solid tumor